Weight regain after stopping a GLP-1: what the evidence shows

The study, published in Lancet eClinicalMedicine (PIIS2589-5370(26)00043-X), analyzed weight regain trajectories after patients stopped GLP-1 receptor agonist therapy across multiple trials and real-world datasets.

The headline finding: at one year post-cessation, patients had regained approximately 60% of the weight they had lost during GLP-1 treatment. Weight regain began quickly — often within weeks of stopping — and the trajectory was fairly consistent across the studies analyzed. The analysis found that regain begins to plateau around 60 weeks after stopping, suggesting the body settles into a new weight equilibrium.

To put this concretely: if someone lost 20 kg on a GLP-1 medication and stopped, the analysis suggests they would on average regain approximately 12 kg within one year. This is consistent with what individual trials showed when they followed participants after treatment ended.

The STEP 1 trial extension (semaglutide 2.4 mg) documented weight regain to near-baseline within 12 months after stopping. The SURMOUNT-1 extension (tirzepatide) showed similar patterns. The Lancet meta-regression synthesizes these and other datasets into a clearer trajectory estimate.

The analysis found regain begins within the first several weeks of stopping GLP-1 therapy and accelerates before eventually plateauing. Most of the regain appears to happen in the first six months.

At 24 weeks, placebo participants in the ATTAIN-MAINTAIN trial — people who had stopped injectable GLP-1s and received no further active therapy — showed weight gains of roughly 9 kg from their starting point in that study. This is consistent with the Lancet trajectory.

Individual variation is real. The 60% figure is an average across populations, not a guarantee for any specific person. But the direction is clear enough to make the maintenance conversation worth having before you stop.

GLP-1 receptor agonists work by reducing appetite, slowing gastric emptying, and affecting brain reward pathways related to food. When you stop the medication, those effects go away. Hunger returns — often described by patients as "food noise" coming back — and the physiological signals that drove weight gain reassert themselves.

This isn't a failure of the medication. Obesity is a chronic, relapsing condition, recognized as such by the American Medical Association, the American Association of Clinical Endocrinology, and other major medical bodies. Managing it long-term with medication is analogous to managing blood pressure or diabetes with medication: stopping the treatment generally means the underlying condition reasserts itself.

The evidence on weight regain after stopping GLP-1s is, in that sense, evidence of how well the drugs work — and a reminder that the treatment question doesn't end at goal weight.

Real-world data cited in the Lancet analysis suggest roughly 50% of patients with obesity discontinue GLP-1 therapy within 12 months of starting. This number deserves scrutiny.

Common reasons for discontinuation include: cost and insurance coverage loss, side effects (particularly gastrointestinal), reaching goal weight and assuming the medication is no longer needed, or supply disruptions.

Many of these are addressable with planning. If cost is the concern, dose titration options, manufacturer savings programs, or maintenance strategies can be explored with your prescriber. If the concern is side effects, adjustments are often possible. If you're stopping because you've reached your goal weight, the Lancet data make a strong case for having a maintenance plan before you do.

The Lancet analysis is a meta-regression — it synthesizes data across studies with different GLP-1 drugs, doses, patient populations, and follow-up durations. The 60% figure is a central estimate, not a guarantee, and individual responses will vary.

Whether a step-down strategy — transitioning from an injectable to an oral GLP-1 — produces better long-term outcomes than continuing an injectable or stopping is not answered by this analysis. The ATTAIN-MAINTAIN trial data (published Nature Medicine, PMID 42120723) suggests step-down to orforglipron can preserve most prior weight loss at 52 weeks, though orforglipron is not yet FDA-approved as of May 2026.

• What is my long-term plan for maintaining weight loss after I reach my goal?
• If I need to stop my GLP-1 for any reason — cost, side effects, insurance — what should I expect and how do we manage it?
• Is there a maintenance dosing or step-down approach that makes sense for my situation?
• How do we monitor for metabolic changes if my weight starts to return?

• Your baseline weight and the amount lost, so you and your prescriber have a clear maintenance target
• Hunger levels and food noise changes if you reduce your dose or stop
• Cardiometabolic markers (blood glucose, blood pressure, lipids as relevant) — these can shift with weight changes

The weight regain data aren't an argument against starting GLP-1 therapy. They're an argument for treating it as a long-term medical decision from the start.

Talk to your prescriber about your long-term plan before you reach your goal weight — and ask specifically: what is our plan if I ever need to stop?

thelancet.com

pmc.ncbi.nlm.nih.gov